EN DE
STOCK COMPARISON

Ajanta Pharma vs Jiangsu Hengrui Medicine Co: Fair Value & Quality

Both stocks run through our valuation models. Here is how Ajanta Pharma (AJANTPHARM) and Jiangsu Hengrui Medicine Co (600276) compare, as of Aug 3, 2026.

As of Aug 3, 2026, Fair Value Calculator sees Jiangsu Hengrui Medicine Co as the less overvalued of the two: Ajanta Pharma trades at ₹3,465 versus a fair value of ₹1,410 (-59%), while Jiangsu Hengrui Medicine Co trades at ¥54.08 versus ¥25.94 (-52%).
Ajanta Pharma
AJANTPHARM.NSE · INR · Health Care
-59%
upside to fair value
overvalued
Price₹3,465
Fair Value₹1,410
Quality71/100
Jiangsu Hengrui Medicine Co
600276.SHG · CNY · Health Care
-52%
upside to fair value
overvalued
Price¥54.08
Fair Value¥25.94
Quality60/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Ajanta PharmaJiangsu Hengrui Medicine Co
Valuation
37.7×P/E (TTM)43.6×
7.31×P/S (TTM)10.84×
8.81×P/B5.76×
26.6×EV/EBITDA33.0×
PEG0.93×
0.9%Dividend yield0.4%
₹28.00Dividend per share¥0.20
Profitability
19%Net margin25%
23%Operating margin32%
25%Return on equity15%
15%Return on assets9%
Growth
22%Revenue growth (YoY)13%
13.7%Avg. growth/yr (3Y)13.9%
13.9%Avg. growth/yr (5Y)2.5%
Balance & size
$4BMarket cap$52B
expensiveGrowth qualityhealthy

Ajanta Pharma leads: 8 to 4 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Ajanta Pharmaof which business quality 60 · market factors 79 Jiangsu Hengrui Medicine Coof which business quality 68 · market factors 44
ProfitabilityMargins and returns on capital today
81
63
Quality GrowthAre margins and returns improving?
39
41
CashflowEarnings quality: real cash, not paper profit
17
82
Fin. StrengthBalance sheet, leverage, solvency risk
81
100
InvestmentDisciplined investing over empire-building
59
27
Low VolatilityCalm price path (market factor)
88
78
MomentumPrice trend over the last 3–12 months (market factor)
71
31
52W MomentumDistance to the 52-week high (market factor)
82
29
Net IssuanceBuybacks instead of dilution
87
64

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Ajanta Pharma

DCF Models₹1,497
Earnings-Based₹1,260
Dividend Discount₹535
Multiples₹1,333
Asset-Based₹243
Growth DCF₹786
Economic Profit₹1,059
Growth Earnings₹1,785

26 of 26 models see the stock below the current price.

Jiangsu Hengrui Medicine Co

DCF Models¥37.11
Earnings-Based¥21.29
Dividend Discount¥3.82
Multiples¥22.37
Asset-Based¥6.44
Growth DCF¥38.47
Economic Profit¥18.21
Growth Earnings¥29.68

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Ajanta Pharma
Bear ₹711Fair Value ₹1,410Bull ₹2,086
₹3,465 = current price (white tick)
Jiangsu Hengrui Medicine Co
Bear ¥19.95Fair Value ¥25.94Bull ¥40.28
¥54.08 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Ajanta Pharma · Health Care

Quality score71 · Top 25%
Fair value upside-59% · below median

Jiangsu Hengrui Medicine Co · Health Care

Quality score60 · Top 25%
Fair value upside-52% · below median

Bottom line

As of Aug 3, 2026, Fair Value Calculator sees Jiangsu Hengrui Medicine Co as the less overvalued of the two: Ajanta Pharma trades at ₹3,465 versus a fair value of ₹1,410 (-59%), while Jiangsu Hengrui Medicine Co trades at ¥54.08 versus ¥25.94 (-52%).

Ajanta Pharma has the higher quality score (71/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.